Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

BACKGROUND: Despite preventive vaccines for oncogenic human papillomaviruses (HPVs), cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative and can lead to long-term reproductive morbidity. We assessed whether VGX-3100, synthetic plasmids targeting HPV-16 and HPV-18...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet
Autores principales: Trimble, Cornelia L, Morrow, Matthew P, Kraynyak, Kimberly A, Shen, Xuefei, Dallas, Michael, Yan, Jian, Edwards, Lance, Parker, R Lamar, Denny, Lynette, Giffear, Mary, Brown, Ami Shah, Marcozzi-Pierce, Kathleen, Shah, Divya, Slager, Anna M, Sylvester, Albert J, Khan, Amir, Broderick, Kate E, Juba, Robert J, Herring, Timothy A, Boyer, Jean, Lee, Jessica, Sardesai, Niranjan Y, Weiner, David B, Bagarazzi, Mark L
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4888059/
https://ncbi.nlm.nih.gov/pubmed/26386540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00239-1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares